Tafluprost,Isopropyl (5Z)-7-{(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxy-1-buten-1-yl]-3,5-dihydroxycyclopentyl}-5-heptenoate(CAS: 209860-87-7)

Tafluprost (MK2452, AFP-168) is a selective prostaglandin F (FP) receptor agonist that effectively lowers intraocular pressure (IOP) in preclinical models. In studies using normotensive and glaucomatous rabbits and monkeys, topical administration of tafluprost reduced IOP by 25–35%, demonstrating dose-dependent ocular hypotensive activity. It enhanced uveoscleral outflow with high receptor selectivity and minimal off-target effects, while showing efficient corneal penetration and sustained ocular residence. Pharmacokinetic analyses indicated low systemic exposure, reducing potential side effects. These findings support tafluprost’s potential as a safe and effective therapy for glaucoma and ocular hypertension, providing sustained IOP reduction and protection against optic nerve damage. Tafluprost (AFP-168) is an anti-glaucoma prostaglandin (PG) analog. Tafluprost can inhibit the apoptosis of retinal ganglion cells (RGCs) and rat RGCs cells. Tafluprost promotes axon regeneration by regulating Zn2+-mTOR pathway, inhibits intracellular lipid accumulation in human preorbital adipocytes. Tafluprost can be used in the study of optic nerve injury in glaucoma.